Philogen S.p.A.
Quick facts
Phase 3 pipeline
- Daromun · Other
- L19IL2 + L19TNF · Oncology
L19IL2 + L19TNF is a bispecific antibody-cytokine fusion combination that targets tumor vasculature via the L19 antibody while delivering IL-2 and TNF directly to the tumor microenvironment.
Phase 2 pipeline
- F8IL10
- Intratumoral injections of L19IL2 · Oncology
L19IL2 is an immunocytokine that targets the EDB domain of fibronectin, which is overexpressed in tumor vasculature, and delivers IL-2 to the tumor microenvironment to stimulate an anti-tumor immune response. - L19TNF
- L19TNF and CCNU
- L19TNF and CCNU in recurrent astrocytoma
- L19TNF and TMZ · Oncology
TNF-alpha inhibitor - L19TNF and TMZ in recurrent astrocytoma
- L19TNF monotherapy
- L19TNF monothery in recurrent oligodendroglioma
Phase 1 pipeline
- [177Lu]Lu-OncoFAP-23
- [68Ga]Ga-OncoACP3
- [68Ga]Ga-OncoCAIX
- [68Ga]Ga-OncoFAP administration
- F16IL2 in combination with paclitaxel
- IL12-L19L19
- L19IL2 at RD - Ph II
- L19IL2 - Ph I
- Nivolumab, fixed dose
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: